Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Endocrine 1Dermatologic 1Breast 1

Conditions

Melanoma 4Breast Neoplasms 2Uveal Melanoma 1Recurrence 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Cutaneous or Subcutaneous Tumors Where There is no Comparable or Satisfactory 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1Carcinoid Tumor 1

Interventions

Sorafenib 79pembrolizumab 37Bevacizumab 36Nivolumab 33lenvatinib 30atezolizumab 24durvalumab 17Oxaliplatin 12Ipilimumab 12regorafenib 9Capecitabine 9tremelimumab 8Injections 8Doxorubicin 8tislelizumab 7sintilimab 7Fluorouracil 7cabozantinib 6budigalimab 6brivanib 6Ramucirumab 6toripalimab 5Gemcitabine 5Everolimus 5Cyclophosphamide 5ADI PEG20 5fludarabine 4Sunitinib 4Leucovorin 4E-7386 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Hepatocellular × Rose Bengal × Clear all
NCT00986661 2022-11-02

A Study to Assess PV-10 Chemoablation of Cancer of the Liver

Provectus Pharmaceuticals

Phase 1 Unknown
78 enrolled
BreastDermatologicEndocrineGastrointestinalThoracic

Uveal Melanoma, Breast Neoplasms, Carcinoid Tumor, Colonic Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡